CN110907583A - 一种洛索洛芬或其钠盐中有关物质的分离方法 - Google Patents
一种洛索洛芬或其钠盐中有关物质的分离方法 Download PDFInfo
- Publication number
- CN110907583A CN110907583A CN201911091258.6A CN201911091258A CN110907583A CN 110907583 A CN110907583 A CN 110907583A CN 201911091258 A CN201911091258 A CN 201911091258A CN 110907583 A CN110907583 A CN 110907583A
- Authority
- CN
- China
- Prior art keywords
- methanol
- loxoprofen
- solution
- sodium
- test solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960002373 loxoprofen Drugs 0.000 title claims abstract description 53
- 238000000034 method Methods 0.000 title claims abstract description 19
- 239000000126 substance Substances 0.000 title claims abstract description 14
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 title claims abstract description 12
- 159000000000 sodium salts Chemical class 0.000 title claims abstract description 11
- 238000000926 separation method Methods 0.000 claims abstract description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 165
- 239000012085 test solution Substances 0.000 claims description 34
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 28
- 239000012535 impurity Substances 0.000 claims description 27
- 239000000243 solution Substances 0.000 claims description 27
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 24
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 24
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 24
- 238000002360 preparation method Methods 0.000 claims description 16
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 14
- 238000007865 diluting Methods 0.000 claims description 12
- 238000005303 weighing Methods 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 10
- 239000012088 reference solution Substances 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 9
- 238000005520 cutting process Methods 0.000 claims description 9
- 239000011505 plaster Substances 0.000 claims description 8
- 230000001502 supplementing effect Effects 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical group CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 3
- 230000005526 G1 to G0 transition Effects 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims description 2
- 238000010829 isocratic elution Methods 0.000 claims description 2
- 238000004811 liquid chromatography Methods 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 230000009466 transformation Effects 0.000 claims description 2
- WORCCYVLMMTGFR-UHFFFAOYSA-M loxoprofen sodium Chemical compound [Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 WORCCYVLMMTGFR-UHFFFAOYSA-M 0.000 abstract description 44
- 238000001514 detection method Methods 0.000 abstract description 21
- 238000002474 experimental method Methods 0.000 abstract description 3
- 238000012827 research and development Methods 0.000 abstract 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 abstract 1
- 239000012488 sample solution Substances 0.000 description 17
- 239000012071 phase Substances 0.000 description 16
- 239000000499 gel Substances 0.000 description 14
- 239000000523 sample Substances 0.000 description 10
- 230000014759 maintenance of location Effects 0.000 description 8
- 238000009210 therapy by ultrasound Methods 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000010008 shearing Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 238000012356 Product development Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 238000005220 pharmaceutical analysis Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229960003594 sodium salt ibuprofen Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/89—Inverse chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
- G01N2030/062—Preparation extracting sample from raw material
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
序号 | 杂质名称 | 结构式 |
1 | 洛索洛芬钠杂质DP-1 | |
2 | 洛索洛芬钠杂质DP-2 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911091258.6A CN110907583B (zh) | 2019-11-13 | 2019-11-13 | 一种洛索洛芬或其钠盐中有关物质的分离方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911091258.6A CN110907583B (zh) | 2019-11-13 | 2019-11-13 | 一种洛索洛芬或其钠盐中有关物质的分离方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110907583A true CN110907583A (zh) | 2020-03-24 |
CN110907583B CN110907583B (zh) | 2021-03-02 |
Family
ID=69817030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911091258.6A Active CN110907583B (zh) | 2019-11-13 | 2019-11-13 | 一种洛索洛芬或其钠盐中有关物质的分离方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110907583B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115236255A (zh) * | 2022-08-04 | 2022-10-25 | 迪沙药业集团有限公司 | 一种洛索洛芬钠有关物质检测方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2128123A1 (en) * | 2007-01-29 | 2009-12-02 | Medrx Co., Ltd. | Salt of nonsteroidal anti-inflammatory drug and organic amine compound and use thereof |
CN103044356A (zh) * | 2011-10-13 | 2013-04-17 | 湖南九典制药有限公司 | 合成左西替利嗪的新方法及其关键中间体 |
CN105380929A (zh) * | 2015-11-23 | 2016-03-09 | 蚌埠丰原涂山制药有限公司 | 一种含洛索洛芬钠的药物组合物及其制备方法 |
CN108440274A (zh) * | 2018-03-06 | 2018-08-24 | 大桐制药(中国)有限责任公司 | 一种高纯度非甾体消炎药洛索洛芬钠的合成方法 |
CN109394735A (zh) * | 2018-11-09 | 2019-03-01 | 北京德默高科医药技术有限公司 | 具有高溶解度的布洛芬或其结构类似物经皮给药系统 |
CN110261531A (zh) * | 2019-07-27 | 2019-09-20 | 湖南九典制药股份有限公司 | 一种洛索洛芬或其钠盐中有关物质的检测方法 |
-
2019
- 2019-11-13 CN CN201911091258.6A patent/CN110907583B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2128123A1 (en) * | 2007-01-29 | 2009-12-02 | Medrx Co., Ltd. | Salt of nonsteroidal anti-inflammatory drug and organic amine compound and use thereof |
CN103044356A (zh) * | 2011-10-13 | 2013-04-17 | 湖南九典制药有限公司 | 合成左西替利嗪的新方法及其关键中间体 |
CN105380929A (zh) * | 2015-11-23 | 2016-03-09 | 蚌埠丰原涂山制药有限公司 | 一种含洛索洛芬钠的药物组合物及其制备方法 |
CN108440274A (zh) * | 2018-03-06 | 2018-08-24 | 大桐制药(中国)有限责任公司 | 一种高纯度非甾体消炎药洛索洛芬钠的合成方法 |
CN109394735A (zh) * | 2018-11-09 | 2019-03-01 | 北京德默高科医药技术有限公司 | 具有高溶解度的布洛芬或其结构类似物经皮给药系统 |
CN110261531A (zh) * | 2019-07-27 | 2019-09-20 | 湖南九典制药股份有限公司 | 一种洛索洛芬或其钠盐中有关物质的检测方法 |
Non-Patent Citations (7)
Title |
---|
L.SRIDHAR 等: "LC-ESI-MS/MS studies on saxagliptin and its forced degradation products", 《ANALYTICAL METHODS》 * |
RAVI N.TIWARI 等: "Identification and characterization of degradation products of raltegravir using LC,LC-MS/TOF,and MS", 《JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES》 * |
TOMONORI MURAKAMI 等: "Identification of degradation products in loxoprofen sodium adhesive tapes by liquid chromatography-mass spectrometry and dynamic pressurized liquid extraction–solid-phase extraction coupled to liquid chromatography-nuclear magnetic resonance spectroscopy", 《JOURNAL OF CHROMATOGRAPHY A》 * |
蒋凯 等: "HPLC法测定国产洛索洛芬钠片人体相对生物利用度", 《江苏医学与临床研究》 * |
袁浩宇 等: "RP-HPLC法测定洛索洛芬钠片的含量及有关物质", 《中国药房》 * |
陆步实 等: "反相高效液相色谱法测定洛索洛芬钠的含量及其有关物质", 《中国新药杂质》 * |
马永潮 等: "利用高效液相色谱法测定氯索洛芬中间体", 《浙江树人大学学报》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115236255A (zh) * | 2022-08-04 | 2022-10-25 | 迪沙药业集团有限公司 | 一种洛索洛芬钠有关物质检测方法 |
CN115236255B (zh) * | 2022-08-04 | 2023-08-25 | 迪沙药业集团有限公司 | 一种洛索洛芬钠有关物质检测方法 |
Also Published As
Publication number | Publication date |
---|---|
CN110907583B (zh) | 2021-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112748206B (zh) | 一种同时适应人血浆中24种抗癫痫药物测定的高效液相色谱分析方法 | |
CN110261531B (zh) | 一种洛索洛芬或其钠盐中有关物质的检测方法 | |
CN100577677C (zh) | 络石藤总木脂素提取物,提取方法及该提取物和其中有效成分的医药用途 | |
CN102920674B (zh) | 一种硫酸羟氯喹片的制备工艺 | |
CN101982179B (zh) | 一种小儿氨酚黄那敏颗粒 | |
CN106770807A (zh) | 一种氟比洛芬酯注射液中有关物质的检测方法 | |
CN110907583B (zh) | 一种洛索洛芬或其钠盐中有关物质的分离方法 | |
CN102805767B (zh) | 具有抗淋球菌作用的热淋清颗粒原料头花蓼提取物 | |
CN103191116A (zh) | 一种氢溴酸右美沙芬愈创木酚甘油醚口服液及其制备方法 | |
CN111678999B (zh) | 一种盐酸阿比多尔有关物质检测方法 | |
CN110927279B (zh) | 一种盐酸咪达普利有关物质的分离方法 | |
CN104122361B (zh) | 利用高效液相色谱分析氨美愈软胶囊的方法 | |
CN111454271A (zh) | 一种吡咯烷羧酸类化合物的钠盐、结晶形式及其制备方法 | |
JP2007147541A (ja) | 血漿中クロルフェニラミン及びフェニレフリンの同時定量方法 | |
CN103878036A (zh) | 一种强极性碱性化合物的分离分析或分离制备方法 | |
CN110849994A (zh) | 一种利伐沙班中有关物质的分离方法 | |
Tang et al. | Liver, blood microdialysate and plasma pharmacokinetics of matrine following transdermal or intravenous administration | |
CN108872405B (zh) | 一种洛度沙胺氨丁三醇有关物质的hplc分析检测方法 | |
CN106317140B (zh) | 京尼平苷酸的新晶型及其制备方法和应用 | |
CN1762359A (zh) | 乌药生物碱及其制备方法与在制药中的应用 | |
CN102002092B (zh) | 3-羟基丹参酮ⅱa磺酸钠及其制备方法和用途 | |
CN103787958B (zh) | 一种马来酸氯苯那敏化合物及其药物组合物 | |
CN104569172A (zh) | 一种用液相色谱检测苯甲酸阿格列汀片溶出度的方法 | |
CN112480001A (zh) | 一种制备左旋吡喹酮手性中间体的方法及组合物 | |
CN104306352A (zh) | 一种光甘草定微囊及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhu Zhihong Inventor after: Xiao Wending Inventor after: He Li Inventor after: Wen Feng Inventor after: Xie Chaojun Inventor after: Zheng Liang Inventor before: Xie Chaojun Inventor before: Wen Feng Inventor before: He Li Inventor before: Wang Yi Inventor before: Xiao Wending Inventor before: Zheng Xiahui |